Physician profile
Helen E Rhodes
NPI 1043311194
$79,705.07
in general payments reported to CMS, 2019-2025
16 companies · $29.83 in 2025
The $29.83 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $52K · 2021: $9,194 · 2022: $262 · 2025: $29.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $75,821.00 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $2,305.77 | 2019 | |
| Conmed Corporation | $800.00 | 2019 | |
| Novo Nordisk INC | $229.30 | 2021-2022 | |
| Millicent US INC | $177.04 | 2019-2021 | |
| Medtronic, INC. | $121.59 | 2022 | |
| Hologic Sales and Service, LLC | $67.09 | 2020-2025 | Fetal Fibronectin Enzyme Immunoassay |
| Duchesnay USA Incorporated | $37.63 | 2019 | |
| Abbvie INC. | $29.43 | 2022 | |
| Therapeuticsmd, INC. | $27.85 | 2019 | |
| Arbor Pharmaceuticals, INC. | $22.59 | 2019 | |
| Amgen INC. | $15.58 | 2019 | |
| Exeltis, USA INC. | $13.29 | 2019 | |
| Allergan, INC. | $12.81 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.40 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Rhodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.